Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Pancreatitis
Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
June 26th, 2009
Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) announced interim results from a retrospective study including nearly 260,000 patients that showed the risk of acute pancreatitis among patients initiating therapy with BYETTA(R) (exenatide) injection was not increased compared to patients initiating other antidiabetic therapies. These findings were presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) in New Orleans. The retrospective study used data accrued over three years from a large, geographically diverse U.S. health care insurance claims database to examine the risk of acute pancreatitis in more...
Source: Health Business Week (2009-06-26)
|
